文献速递头颈部肿瘤放疗姑息放疗与转移瘤

多模态预后模型预测初诊转移性鼻咽癌一线免疫化疗后生存

Multimodal prognostic model for de novo metastatic nasopharyngeal carcinoma after first-line immunochemotherapy.
PubMed 文献 · Radiother Oncol · 2025-07-01

本研究纳入268例接受一线PD-1抑制剂联合化疗的初诊转移性鼻咽癌患者,基于MRI影像组学、HE病理组学和临床特征构建临床-影像组学-病理组学(CRP)预后模型。CRP模型在训练集、内部和外部验证集的C-index分别为0.823、0.787和0.772,优于临床-影像组学模型(均p<0.001)。低风险组接受局部区域放疗的患者生存更优(p=0.009)。

要点

  • CRP模型可较准确预测初诊转移性鼻咽癌一线免疫化疗后生存。
  • 低风险患者后续接受局部区域放疗可能进一步改善生存。
  • CRP模型预测效能优于临床-影像组学模型。

核心结论

  • CRP模型能准确预测初诊转移性鼻咽癌患者一线免疫化疗后的生存。
  • 低风险患者接受后续局部区域放疗可能进一步改善生存结局。

研究设计与样本

  • 研究纳入268例接受一线PD-1抑制剂联合化疗的初诊转移性鼻咽癌患者。
  • 从鼻咽MRI提取影像组学特征、从HE染色全切片图像提取病理组学特征,并结合临床和形态学特征构建模型。
  • 构建临床模型、临床-影像组学(CR)模型和临床-影像组学-病理组学(CRP)模型并比较效能。

主要发现

  • CRP模型在训练集、内部验证集和外部验证集的C-index分别为0.823(0.751-0.895)、0.787(0.675-0.899)和0.772(0.569-0.974)。
  • 综合判别改善检验显示,CRP模型在训练集、内部验证集和外部验证集均优于CR模型(均p<0.001)。
  • 基于最有效模型分层的低风险组中,接受局部区域放疗的患者生存优于未接受者(p=0.009)。

关键数值与推荐

  • CRP模型训练集C-index为0.823(0.751-0.895)。
  • CRP模型内部验证集C-index为0.787(0.675-0.899)。
  • CRP模型外部验证集C-index为0.772(0.569-0.974)。
  • CRP模型对比CR模型的综合判别改善检验均p<0.001。
  • 低风险组局部区域放疗对比未放疗的生存差异p=0.009。

临床怎么用

  • 可利用CRP模型对初诊转移性鼻咽癌一线免疫化疗患者进行风险分层。
  • 对低风险患者可考虑后续局部区域放疗以改善生存。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Immunochemotherapy has been recommended as a first-line treatment for patients with de novo metastatic nasopharyngeal carcinoma (dmNPC), but there is a lack of effective ways to predict survival benefits. The objective of this study was to utilize multimodal data to construct a prognostic model for patients undergoing immunochemotherapy, to facilitate subsequent treatment decisions. MATERIAL AND METHODS: A total of 268 patients with dmNPC who received first-line programmed death-1(PD-1) inhibitor in combination with a chemotherapy regimen were enrolled. Radiomics and pathomics features were extracted from magnetic resonance (MR) images and whole slide images (WSI) of nasopharyngeal hematoxylin-eosin staining (HE) slides to construct radiomics and pathomics scores. Clinical and morphological features were collected for analysis. A clinical prognostic model, a clinical-radiomics (CR) prognostic model, and a clinical-radiomics-pathomics (CRP) prognostic model were constructed using independent prognostic features, radiomics scores, and/or pathomics scores. The performance of these models was described and compared. The survival benefits of subsequent radiotherapy were investigated in patients with different risk levels based on the most effective model. RESULTS: The C-indexes of the CRP model in the training cohort, internal and external validation cohort were 0.823 (0.751-0.895), 0.787 (0.675-0.899), and 0.772 (0.569-0.974), respectively. After the integrated discrimination improvement test, the CRP model demonstrated superior efficacy compared to the CR model in the training cohort, internal validation cohort, and external validation cohort (all p < 0.001). In the low-risk group, patients receiving locoregional radiotherapy achieved better survival outcomes compared to those who did not (p = 0.009). CONCLUSION: The CRP model is capable of accurately predicting the survival of patients with dmNPC after first-line immunochemotherapy. In patients with low risk, the addition of subsequent locoregional radiotherapy may further improve the survival outcomes.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Liu ZQ, Zang SB, OuYang PY, et al. Multimodal prognostic model for de novo metastatic nasopharyngeal carcinoma after first-line immunochemotherapy. Radiother Oncol. 2025. PMID: 40609867. doi:10.1016/j.radonc.2025.111010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。